Kilimanjaro Altitude Sickness
AMS, HACE, and HAPE explained. Real incidence data. Symptom checklists. Prevention protocols. What to do if altitude sickness hits — and how our guides keep climbers safe.
Altitude sickness is the defining medical reality of Kilimanjaro. It accounts for the majority of summit failures and virtually all medical evacuations. Yet it remains poorly understood by most first-time climbers — often dismissed as something that happens to unfit people or that can be trained away. Neither is true.
This page covers the science, symptoms by severity, real incidence data, prevention strategies, and what to do if altitude sickness affects you or someone in your group on the mountain.
What Is Altitude Sickness on Kilimanjaro?
Altitude sickness is the common name for Acute Mountain Sickness (AMS) — a collection of symptoms that occur when the body is exposed to lower atmospheric pressure and reduced oxygen availability faster than it can adapt. The technical term is hypobaric hypoxia: low pressure plus low oxygen.
At Kilimanjaro's summit (5,895m), barometric pressure is approximately 340-350mmHg compared to 760mmHg at sea level. Oxygen availability at the summit is roughly 40% lower than at sea level. Every climber — regardless of fitness — is hypoxic at altitude. The question is not whether hypoxia affects you; it is whether it produces symptoms severe enough to impair your ability to continue.
The body can adapt to altitude given sufficient time. This process — called acclimatisation — involves producing more red blood cells, increasing ventilation, and improving how muscles use oxygen. It takes days, not hours. Kilimanjaro's danger is that climbers ascend faster than acclimatisation can occur, particularly above 4,000m where the margin between manageable hypoxia and dangerous hypoxia narrows.
Altitude Sickness Incidence on Kilimanjaro — What the Data Shows
Field studies across multiple operators. Headache is the most common presenting symptom.
Affects roughly 1 in 4 climbers. Requires stopping ascent and potentially descending.
Rare but life-threatening. Estimated 2-10 cases per 2,000 climbers. All require emergency descent.
Slightly more common than HACE. Often develops at night during sleep. Can be fatal if not descending.
No verified deaths from altitude sickness alone on Kilimanjaro in the past decade. All fatalities involve delayed evacuation, pre-existing conditions, or a combination of factors.
The Three Conditions: AMS, HACE, and HAPE
Altitude illness exists on a spectrum. Understanding where you are on that spectrum — and what it means — is the most important safety skill a Kilimanjaro climber can have.
Acute Mountain Sickness — Most Common, Treatable
AMS is the mildest and most common form of altitude illness. It presents as a cluster of symptoms similar to a bad hangover: headache, nausea or loss of appetite, fatigue, dizziness, and difficulty sleeping. It affects the majority of climbers above 3,500m and is not dangerous if managed correctly.
The headache of AMS is typically a dull, persistent ache that worsens when you bend forward or exert yourself. It is caused by mild swelling of the brain's blood vessels in response to hypoxia. It is not a migraine and is not localised to one side of the head.
Treatment: Stop ascending. Rest at current altitude. Take paracetamol or ibuprofen for headache. Drink 1-2 litres of additional water. Monitor with the Lake Worth Score. If symptoms do not improve within 12-24 hours or worsen, descend a minimum of 500m. Symptoms resolve within 24-48 hours at the same altitude in most mild cases.
Lake Worth Score — Mild AMS (2-4 points)
- • Headache: 1 point (mild) or 2 points (severe, not relieved by paracetamol)
- • Nausea/vomiting: 1-2 points
- • Fatigue: 1-2 points
- • Dizziness: 1-2 points
Score 2-4 = mild AMS. Rest and monitor. Do not ascend until symptoms resolve.
High Altitude Cerebral Edema — Medical Emergency
HACE is the progression of untreated AMS to life-threatening cerebral oedema — fluid building up in the brain. It develops when the brain swells from hypoxia-induced capillary leakage. The key distinguishing feature is neurological impairment: confusion, disorientation, loss of coordination, and behavioural changes that are not explained by exhaustion alone.
The hallmark physical sign is ataxia — an inability to walk in a straight line heel-to-toe. Ask the climber to draw a line on the ground and walk heel-to-toe along it. Any unsteadiness or falling off the line is a HACE warning sign. This is why experienced guides ask climbers to perform this test twice daily.
Other symptoms include severe drowsiness, confusion, slurred speech, hallucinations, and loss of consciousness. HACE typically develops above 4,500m and can kill within 24-48 hours if the climber does not descend. There are no effective field treatments beyond descent and supplemental oxygen.
Treatment: Descend immediately. Do not wait for morning. Do not wait to see if the climber improves. Every hour of delay worsens outcomes. Administer supplemental oxygen at 2-4 litres per minute if available. Use a Gamow bag (portable hyperbaric chamber) if available and descent is not immediately possible. HACE does not resolve at altitude. It only gets worse.
Lake Worth Score — Suspected HACE (9+ points)
- • Severe headache not responding to medication
- • Ataxia — cannot walk heel-to-toe in a straight line
- • Confusion, disorientation, behavioural changes
- • Extreme fatigue — climber cannot stand
- • Loss of consciousness in severe cases
HACE is a medical emergency. Descent is the ONLY treatment that works. Evacuate immediately.
High Altitude Pulmonary Edema — Medical Emergency
HAPE is a buildup of fluid in the lungs caused by hypoxia-induced increases in pulmonary artery pressure. As the lungs struggle to oxygenate blood, pressure in the pulmonary circulation rises, causing fluid to leak from capillaries into the lung tissue and air sacs. This further impairs oxygen uptake — a dangerous positive feedback loop.
HAPE typically develops at night during sleep — which makes it particularly dangerous on Kilimanjaro, where climbers sleep at altitude (Barafu Camp at 4,600m is a common onset point). The early symptom is breathlessness at rest — not just on exertion. A climber who cannot catch their breath sitting still has HAPE until proven otherwise.
Other symptoms include persistent dry cough progressing to wet cough with frothy or pink sputum, chest tightness, low oxygen saturation readings significantly below expected values, and cyanosis (blue tinge to lips and fingernails). HAPE can develop within hours of arriving at a new altitude and can be fatal within 24 hours.
Treatment: Same as HACE — immediate descent is the only definitive treatment. Administer supplemental oxygen at 4-6 litres per minute. Keep the climber warm (cold worsens pulmonary vasoconstriction). A Gamow bag can stabilise the patient for transport. HAPE is the most common cause of altitude-related death on Kilimanjaro when evacuation is delayed.
HAPE Warning Signs — Act Immediately
- • Breathlessness at rest (not just on exertion)
- • Persistent cough — dry at first, then wet with frothy sputum
- • Chest tightness or pain
- • Oxygen saturation significantly below 80% at rest
- • Cyanosis — blue or grey lips and fingernails
HAPE is a medical emergency. Begin descent immediately. Supplemental oxygen is critical en route.
Who Is at Risk? The Uncomfortable Truth
There is no reliable way to predict who will develop altitude sickness on Kilimanjaro. This is the most important and least understood fact about the condition. Fitness does not protect you. Age does not protect you. Gender does not protect you. Prior altitude experience does not reliably protect you.
Multiple peer-reviewed studies have confirmed this. A 2011 study of 834 climbers on Kilimanjaro found no correlation between AMS incidence and age, sex, BMI, or self-reported fitness. A 2018 meta-analysis reached the same conclusion. The only consistent predictor across studies is the rate of ascent — faster itineraries produce higher AMS rates.
This means you cannot look at an ultra-marathon runner and assume they will handle altitude better than a casual hiker. They may, or may not. What we do know is that the slower you ascend, the lower your risk. This is why the most impactful decision you can make before booking your climb is choosing the right itinerary.
What DOES and DOES NOT predict altitude sickness on Kilimanjaro
NOT predictive:
- • Fitness level (aerobic capacity, running, cycling)
- • Age (children and older adults climb successfully)
- • Gender (studies show no significant difference)
- • Prior altitude experience (Mt. Kenya, Alps, Rockies)
- • Smoking history
- • Having climbed Kilimanjaro before
- • Body mass or BMI
Consistently predictive:
- • Rate of ascent (faster itineraries = higher risk)
- • Individual physiological susceptibility (genetic, unpredictable)
- • History of previous AMS on any altitude trek
- • Sleeping altitude gain per night (ideally under 500m/night above 3,000m)
Prevention: The Three Most Effective Strategies
You cannot eliminate altitude sickness risk on Kilimanjaro. But three evidence-based strategies measurably reduce both the likelihood and severity of symptoms.
Choose a Longer Itinerary
The single most impactful decision. The 8-day Lemosho Route averages 94% summit success versus 65-70% on the 6-day Machame. The 5-day Marangu averages 45-55%. The difference is acclimatisation time at altitude — specifically the time spent between 4,000m and 5,000m, where the body is most vulnerable to hypoxia. Every additional day above 4,000m measurably improves summit odds. The $200-$400 cost difference between a 6-day and 8-day itinerary is the highest-ROI decision you will make on the mountain.
View Lemosho 8-day itinerary →Climb Pole Pole — Slowly Slowly
Swahili is the language of the mountain for good reason. Pole pole — climb slowly — is the most universally applicable altitude safety advice. The target ascent rate above 3,000m is under 500m of sleeping altitude gain per night. This means the elevation number on your tent is what matters, not your hiking pace. On steep sections, your breathing should be conversational. If you cannot talk in full sentences, you are going too fast. There is no fitness advantage on Kilimanjaro that outweighs the cost of going too fast.
Read our pole pole guide →Acetazolamide (Diamox) — Consider It
Diamox is a carbonic anhydrase inhibitor that accelerates the body's ventilatory adaptation to altitude. It does not mask symptoms — it actually improves physiological adaptation. Studies show it reduces AMS incidence by approximately 40-50% when taken prophylactically. The standard dose is 125mg twice daily, starting 24 hours before ascent above 3,000m and continuing until descent below that altitude. Side effects include tingling in fingers and toes, increased urination, and altered taste of carbonated drinks. Diamox is not a substitute for slow ascent — it is an adjunct to it. Consult your doctor before taking.
See our full prevention guide →
What Our Guides Do Differently
Our guides are trained in wilderness first aid and altitude illness recognition. The difference between our approach and budget operators is not some dramatic intervention on summit night — it is the daily monitoring that catches problems before they become emergencies.
Twice-daily Lake Worth Score assessment for every climber, every morning and evening
Pulse oximetry monitoring at every camp — SpO2 readings below 80% at rest trigger a guide consultation
The pole pole enforcement — our guides will slow you down, regardless of how you feel
Daily health briefings — climbers are taught to self-report symptoms without stigma
Fixed minimum descent triggers — if LLS reaches 5+, descent begins. No negotiation, no see if it improves overnight
Emergency evacuation protocol — our guides carry oxygen and have direct radio contact with Moshi for helicopter evacuation if needed
Pre-climb briefing — every climber receives an altitude sickness orientation before the mountain, in their own language where possible
Related Reading
How Acclimatisation Actually Works
Acclimatisation is not voodoo. It is a suite of measurable physiological adaptations — haematological, ventilatory, and cellular — that develop over days at altitude. Understanding the mechanism makes clear why longer itineraries produce such dramatically better summit rates.
Read the physiology guide →
Frequently Asked Questions
How common is altitude sickness on Kilimanjaro?
Mild Acute Mountain Sickness (AMS) affects approximately 50-77% of Kilimanjaro climbers to some degree, based on multiple field studies. Serious altitude sickness requiring descent — HACE or HAPE — occurs in approximately 0.1-0.5% of climbers. Altitude sickness does not correlate with fitness level, age, gender, or prior altitude experience.
What is the difference between AMS, HACE, and HAPE?
AMS (Acute Mountain Sickness) is the mildest form — headache, nausea, fatigue, loss of appetite. It is common above 3,000m and resolves with rest or descent. HACE (High Altitude Cerebral Edema) is a buildup of fluid in the brain causing confusion, loss of coordination, and disorientation. HAPE (High Altitude Pulmonary Edema) is a buildup of fluid in the lungs causing breathlessness, cough, and chest tightness. Both HACE and HAPE are medical emergencies requiring immediate descent.
Can altitude sickness be prevented on Kilimanjaro?
It cannot be fully prevented — susceptibility is largely genetic and unpredictable. However, it can be significantly managed: choose a longer itinerary (7-8 days rather than 5-6), climb slowly (pole pole — Swahili for slowly slowly), stay well hydrated, avoid alcohol, and consider acetazolamide (Diamox). Our guides use pulse oximetry to detect early hypoxia before symptoms become severe.
Who is most at risk for altitude sickness on Kilimanjaro?
No reliable predictor exists. Fitness, age, gender, prior altitude experience, and smoking status do not reliably predict susceptibility. The only consistent risk factor is the rate of ascent — faster ascents mean higher AMS rates. Climbers who ascended too quickly on previous high-altitude treks (such as Mt. Kenya or the Inca Trail) are at higher risk.
What is the Lake Worth Score and how is it used on Kilimanjaro?
The Lake Worth Score (LLS) is a validated diagnostic tool for assessing AMS severity. Guides assign points for headache (0-2), gastrointestinal symptoms (nausea/vomiting, 0-2), fatigue (0-2), and dizziness (0-2). A score of 2-4 indicates mild AMS. 5-8 indicates moderate AMS requiring descent. 9+ indicates severe AMS consistent with HACE and requires emergency descent. Our guides conduct LLS assessments twice daily on every climb.
Talk to a Guide Before You Climb
If you have questions about altitude, your health, or which route suits you — message us on WhatsApp before you book anything. We will tell you honestly whether you are ready for the climb.
Message Us on WhatsAppPOPULAR ROUTES
Ready to Plan Your Climb?
Every route is a private guided expedition with Mount Kilimanjaro Climb. Kassim will match you to the right route for your fitness level and timeline.